Scivanta Medical Corporation (OTC Bulletin Board: SCVM), today announced that the results of its initial clinical trial for the Scivanta Cardiac Monitoring System (SCMS) clearly indicate that the SCMS can accurately measure cardiac performance as expected by the company. This clinical trial was performed at Kaleida Health/Millard Fillmore Hospital in Buffalo, New York.
The initial clinical trial was designed to obtain data concerning the safety and efficacy of the SCMS by comparing mean left atrial pressure measurements obtained from the SCMS to left ventricular end-diastolic pressure readings measured in a simultaneous left heart catheterization procedure performed by a cardiologist in the cardiac catheterization unit. These measurements of cardiac performance are used by physicians in the critical evaluation of a patient's cardiac health.